Published in Lancet on April 14, 1979
Reversible renal failure during treatment with captopril. Br Med J (1979) 1.35
Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension (2000) 8.84
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ (2001) 4.66
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics (2001) 2.50
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens (1991) 2.06
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Knowledge, attitudes, and practices on hypertension in a country in epidemiological transition. Hypertension (1998) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med (1979) 1.53
The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. N Engl J Med (1988) 1.49
Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis (1972) 1.46
Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest (1982) 1.46
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock (2001) 1.41
Models of experimental hypertension in mice. Hypertension (1996) 1.41
Muscle glycogenolysis during exercise: dual control by epinephrine and contractions. Am J Physiol (1982) 1.40
Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension (1995) 1.40
[Antihypertensive agents used as first line agents: beta-blockers under pressure]. Rev Med Suisse (2006) 1.39
Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet (1971) 1.37
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation (1981) 1.35
Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res (2001) 1.32
Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet (1969) 1.31
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J (1981) 1.19
Captopril and enalapril. Ann Intern Med (1983) 1.16
The nephrotoxicity of cephaloridine. Postgrad Med J (1970) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16
Role of vasopressin in essential hypertension: racial differences. J Hypertens (1997) 1.15
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest (2001) 1.13
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J (1978) 1.12
A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta (2000) 1.12